Results filed 19 October 2026 · Market cap ₹3,845 crore · PE 60.2
GrowthGuidance maintainedPresentation only
Revenue
+75.9%
on a year ago
EBITDA
+83.1%
on a year ago
Profit to shareholders
+116.2%
on a year ago
EBITDA margin
18.7%
−0.6 pts on last quarter
Tatva Chintan reported record consolidated quarterly revenue of ₹2,173 Mn in Q2 FY27, up 76% YoY, driven primarily by strong demand for Structured Directing Agents under EURO 7 regulations. Operating margins remained constrained near 19% as severe solvent cost spikes of 60%-100% and a doubling of transatlantic/European freight rates countered operating leverage benefits. Working capital expansion caused short-term borrowings to climb to ₹1,655.30 Mn, while management expects input cost pressures to normalize by Q3 FY27.
Source: Tatva Chintan Pharma Chem Limited’s filing to NSE, 19 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
These notes are from the presentation and press release. The concall transcript isn’t filed yet; the notes are rewritten when it is.
What stood out
Highest-ever quarterly revenue achieved with 76% YoY top-line growthSourceRevenue from operations reached ₹2,173 Mn in Q2 FY27 compared to ₹1,235 Mn in Q2 FY26 (+76% YoY, +30% QoQ) (Updated Presentation, original page 11).
SDA demand driven by EURO 7 emission standards implementationSourceIn Structured Directing Agents, 'the implementation of EURO 7 emission standards is already translating into a meaningful contribution to our sales' (CMD Message, original page 6).
Margin pressure from solvent price spikes and doubled freight ratesSource'erratic short supplies in some of the solvents which has led to a price increase in these solvents by 60%-100%' and 'rampant increase in global freights, especially, in certain sectors of US and Europe where the increase is more than 100%' (CMD Message, original page 5).
Guidance
Metric
Guidance
Period
Revenue Growth MomentumSource'We foresee the revenue trend growth with similar momentum over the next quarters' (CMD Message, original page 5).
Foresee revenue trend growth with similar momentum over the next quarters
Next quarters of FY27
EBITDA MarginSource'We expect it to normalise withing the third quarter. We foresee... EBITDA margin to resume its healthy trajectory' (CMD Message, original page 5).
Expected to resume healthy trajectory as solvent prices and freights normalize in Q3
Q3 FY27 and beyond
Tailwinds
Strong demand in SDA driven by EURO 7 transitionSourceSDA accounted for 45% of Q2 FY27 revenue, driven by regulatory adoption of EURO 7 emission standards (Updated Presentation, original pages 6 and 12).
Commercialisation traction in Pharma and Agro Intermediates (PASC)Source'recently commercialised agro products performing well and our pharma product beginning to contribute to the business', bringing PASC to 30% of Q2 FY27 revenue (CMD Message, original page 6; Updated Presentation, original page 12).
Operating leverage in personnel and overhead costsSource'achieved significant operating leverage which is depicted by decrease in employee cost by 2% accompanied by decrease in other expenses by 2%' (CMD Message, original page 5).
Headwinds
Sharp surge in input raw material solvent pricesSourcePrice increases in high-volume solvents of 60%-100% due to erratic short supplies pressured overall raw material costs (CMD Message, original page 5).
Escalation in international freight ratesSourceGlobal freight costs increased by over 100% in certain US and European trade sectors (CMD Message, original page 5).
Surge in working capital and short-term debtSourceInventories rose to ₹2,489.10 Mn and trade receivables rose to ₹1,783.77 Mn as of September 30, 2026, leading to short-term borrowings rising to ₹1,655.30 Mn from ₹1,153.63 Mn in March 2026 (Updated Presentation, original pages 14-15).
New businesses and products
new product · Advancing through development, validation, and customer qualification
Semiconductor Chemicals development portfolio
Expected benefit
Building blocks of a new phase of growth and future revenue stream
Risks
Lengthy customer qualification and validation cycles
Source'we continue to make encouraging progress across all five products in our development portfolio, each advancing well through its respective stages of development, validation and customer qualification' (CMD Message, original page 7).
capacity expansion · Progressing in line with planned schedule
Greenfield manufacturing facility
Expected benefit
Provide additional manufacturing capacity for organic expansion and commercialisation of pipeline molecules
Risks
Execution and timely commissioning
Investment
CWIP stood at ₹428.27 Mn as of 30 September 2026 (Updated Presentation, original page 15)
Source'our new greenfield project is progressing in line with the planned schedule... providing the additional manufacturing capacity required to accommodate the organic expansion' (CMD Message, original page 7).
new product · Progressing towards commercialisation and scaling up
Electrolyte Salts & Solutions for hybrid-battery and energy-storage applications
Expected benefit
Broaden market participation in energy storage and super-capacitor applications
Risks
Adoption speed in EV and energy storage segments
Source'hybrid-battery application is progressing towards commercialisation, and additional products are being scaled up for energy-storage applications' (CMD Message, original page 6).
Things to check
Revenue up over 60%: check for an acquisition or a weak year-ago quarter
Substantial increase in short-term debt to fund working capitalSourceShort-term borrowings increased by 43.5% from ₹1,153.63 Mn in March 2026 to ₹1,655.30 Mn in September 2026, reflecting high inventory (₹2,489.10 Mn) and receivables (₹1,783.77 Mn) (Updated Presentation, original pages 14-15).
Presentation errata regarding leverage and RoE metricsSourceAn annexure was filed correcting H1 FY27 RoE from 2.6% to 6.3% and Debt to EBITDA from 4.30x to 1.16x annualized (Updated Presentation, original page 2).
How the call went
Not yet: there’s no transcript.
Numbers against the story
Management describes achieving 'significant operating leverage' while noting EBITDA remained at 'nearly similar levels' due to raw material and freight headwinds. In reality, absolute EBITDA grew 83% YoY (to ₹407 Mn from ₹222 Mn), but EBITDA margin was essentially flat YoY at 19% vs 18% (and down slightly QoQ), demonstrating that operating leverage benefits were largely offset by cost spikes in solvents and freights. Regarding the +60% sales growth screen flag, growth is entirely organic driven by SDA (Euro 7 transition) and PASC ramp-up, rather than acquisitions.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.